Sonja Nelson - Jan 1, 2023 Form 3 Insider Report for Ambrx Biopharma Inc. (AMAM)

Role
Chief Fin. & Operating Officer
Signature
/s/ Sonja Nelson
Stock symbol
AMAM
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/3/2023, 05:32 PM
Previous filing
Feb 11, 2022
Next filing
Jan 31, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AMAM Employee Stock Option (right to buy) Jan 1, 2023 Ordinary Shares 2.57M $2.56 Direct F1, F2
holding AMAM Employee Stock Option (right to buy) Jan 1, 2023 Ordinary Shares 850K $0.64 Direct F2, F3
holding AMAM Employee Stock Option (right to buy) Jan 1, 2023 Ordinary Shares 425K $0.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date.
F2 The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
F3 Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date.